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Sickle cell disease (SCD) is a disorder in which defective hemoglobin causes 
sickling of red blood cells, inducing painful vaso-occlusive crises when blood flow is 
blocked at sites of red blood cell (RBC) clotting that can ultimately result in organ failure 
or death. This work demonstrates that sphingolipid metabolism is dysregulated in SCD 
and that this pathway can be targeted pharmacologically to prevent vaso-occlusion. We 
suggest a pathway in which the sickling of RBCs in SCD activates acid 
sphingomyelinase, altering the distribution and concentration of sphingolipids in the RBC 
membrane and resulting in the production of sphingolipid-rich microparticles that are 
secreted and can interact with cells in circulation. Sphingosine-1-phosphate (S1P) is 
believed to be a key modulator of SCD because it is stored at high concentrations in 
RBCs. Sphingolipid metabolism was confirmed to be dysregulated in SCD; most notably, 
S1P was significantly elevated in RBCs, and plasma, and microparticles, and the activity 
of acid sphingomyelinase and concentration of its byproduct, microparticles, were 
significantly elevated in SCD RBCs. Treatment of monocytes with S1P and SCD RBCs 
increased their adhesion over four-fold to endothelial cells, indicating that altered 
sphingolipid distribution in RBCs may contribute to vaso-occlusion through increasing 
myeloid cell adhesion. A cytokine profile of macrophages treated with SCD 
microparticles suggest that microparticles play a role in this process by increasing the 
secretion of inflammatory cytokines associated with SCD crises, including MIP-1α, IL-6, 
and TNF-α. Pilot in vitro studies in RBCs and in vivo studies in mice implicate that drugs 
targeting the sphingolipid metabolic pathway may be more effective treatment options 





Sickle cell disease (SCD) is a blood disorder caused by a point mutation in the gene for 
hemoglobin (Embury, 1986). Defective hemoglobin results in sickling of red blood cells (RBCs) 
and increased clotting (Belcher et al., 2000; Kaul et al., 2009). As shown in Figure 1, 
macrophages and monocytes, myeloid-derived immune cells, are activated in the disease state 
and adhere at these clots, further contributing to inflammation and vaso-occlusion (Belcher et al., 
2000), which in extreme cases can ultimately result in organ failure and death (Madigan and 
Malik, 2006). The estimated number of people with SCD in the United States is between 70,000 
and 100,000, and in African Americans the disease is observed in 1 out of every 500 births 
(National Institutes of Health, 2012). Currently, SCD treatment entails pain management and 
blood transfusions to replace sickled RBCs, but these methods are not always effective and can 
result in treatment-related complications over time (Harmatz et al., 2000). 
 
Figure 1. Schematic of healthy red blood cell function versus clotting and myeloid cell 
adhesion in SCD. (A) Healthy RBCs can pass easily through blood vessels. (B) Sickled red 
blood cells are less flexible and tend to create clots. Myeloid cells like macrophages and 
monocytes can become activated and adhere at these sites, further blocking blood flow.  
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This work investigates dysregulated sphingolipid metabolism as an underlying cause of 
the pathology of SCD and demonstrates that this pathway is open to pharmacological therapies 
that can be used to treat the disease (Figure 2). Sphingolipids are a family of lipids that play a 
key role in cell membrane dynamics and signaling (van Meer et al., 2008). Sphingosine 1-
phosphate (S1P) is an immunomodulatory sphingolipid that is of special interest for SCD 
because it is highly concentrated in red blood cells (Peest et al., 2008) and is elevated in SCD 
(Awojoodu, unpublished). The Botchwey lab believes that membrane stress induced by RBC 
sickling activates acid sphingomyelinase (SMase), which reduces this stress by converting 
membrane sphingomyelin to ceramide. This process can result in the production of sphingolipid-
rich microparticles derived from the RBC membrane that can be secreted and interact with other 
cells in circulation (Bianco et al., 2009). Microparticles have been shown to be elevated in steady 




Figure 2. Schematic of sphingolipid metabolism and microparticle generation in SS RBC. 
When RBC undergo reversible sickling cycles, their membranes curve, introducing membrane 
stresses caused by the closer interaction of lipids. This increased membrane force activates acid 
sphingomyelinase (A-SMase) on the outer leaflet of the plasma membrane (1). Acid SMase 
hydrolyzes sphingomyelin to form ceramide which has a smaller head group and can cause an 
inward curvature of the membrane which reduces membrane stresses. Sphingomyelin can be 
further metabolized into sphingosine and S1P with alkaline ceramidase (CDase) and Sphingosine 
Kinase (SK1/2), respectively (2). Membrane budding results in the formation of membrane-
derived exosomes (3), containing sphingolipids and proteins, which are internalized into the cell 
and subsequently released into circulation through secretion or hemolysis as microparticles (4).  
 
The synthesis and metabolism of sphingolipids have been described in great detail 
(Hannun et al., 2001; Peest et al., 2008), but it is not understood under what conditions 
sphingolipid metabolism will be altered in diseases like sickle cell disease and how this 
contributes to the disease state. This work determined that sphingolipid metabolism is 
dysregulated in SCD through the quantification of the expression and activity of acid 
sphingomyelinase and several other enzymes in this pathway and the levels of S1P and 
sphingosine in SCD and non-SCD RBCs and microparticles. In addition, THP-1 monocytes and 
macrophages as well as primary peripheral blood mononucleated cells isolated from donors were 
treated with RBCs, microparticles, and S1P, and it was demonstrated that these compounds 
increase the adhesion of myeloid cells. These results suggest a novel pathway through which 
RBC sickling causes sphingolipid metabolism to be dysregulated in SCD, inducing the 
production of sphinglipid-rich microparticles that interact with myeloid cells in circulation and 
increase their adhesion at sites of clotting. This has significant implication for studying the 





Sickle cell disease (SCD) is a blood disorder caused by a point mutation in the gene for 
hemoglobin. Defective hemoglobin results in sickling of red blood cells (Embury, 1986), which 
increases clotting because the misshapen cells are more likely to be caught in smaller vessels and 
capillaries (Conran et al., 2009; Hebbel et al., 1980). Monocytes derived from sickle cell blood 
have been shown to be more activated than normal monocytes (Belcher et al., 2000), and 
presumably macrophages may be more activated as well as they are derived from monocytes. 
Activation makes these cells more adherent, further contributing to inflammation and vaso-
occlusion, which in extreme cases can ultimately result in organ failure and death (Belcher et al., 
2000).  
Sphingolipids are minor components of the cell membrane that can play a key role in 
membrane structure (Piccinini et al., 2010). Sphingolipids tend to aggregate and form lipid 
“rafts” in the cell membrane and alter its structure through the application of curvature stress 
(van Meer et al., 2008). In these locations, conversion of membrane sphingomyelin to ceramide 
by acid sphingomyelinase (SMase) can result in the production of microparticles (MPs) that can 
be secreted and interact with other cells in circulation (Bianco et al., 2009). Microparticles are 
important signaling molecules for innate immunity and have been shown to contain high levels 
of bioactive lipids like sphingosine 1-phosphate (Ratajczak et al., 2006).  
Sphingosine 1-phosphate (S1P) is an anti-inflammatory sphingolipid that is involved in 
the regulation of lymphocyte traffic and many other cellular processes (Hughes et al., 2008). S1P 
is extremely important in regulating cell physiology, as evidenced by lethality in mice unable to 
produce S1P (Olivera et al., 2013). Red blood cells (RBCs) are known reservoirs for S1P; 
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however, S1P is present at low concentrations elsewhere in the body (Peest et al., 2008), 
suggesting that this gradients is significant in the ability of S1P to act with a high degree of 
specificity in regulation (Olivera et al., 2013). 
S1P synthesis and metabolism pathways are well defined (Peest et al., 2008), but the role 
of S1P in sickle cell disease is not clear. This review will examine S1P metabolism and 
regulation of cell physiology, discuss how these results can be applied to the sickle cell disease 
state, and establish the gap that remains in understanding how altered sphingolipid metabolism 
may facilitate vaso-occlusion and inflammation in SCD. 
S1P Metabolism and the Formation of S1P Gradients 
The importance of S1P in regulating physiology is supported by the shown lethality of a 
double knockout of the genes for sphingosine kinase 1 and 2, the enzymes that phosphorylate 
sphingosine to make S1P (Olivera et al., 2013). S1P is present at varied concentrations 
throughout the body in vivo, suggesting that these gradients are significant in the ability of S1P 
to act with a high degree of specificity in regulation (Olivera et al., 2013).  
S1P gradients are formed and maintained in part due to differential but ubiquitous 
metabolism of S1P by different types of cells, including HEK293, Jurkat, LK35.2, HB98, and 
HTC4 cells, and varying locations of these cells in the body (Olivera et al., 2013; Peest et al., 
2008). S1P lyase, which degrades S1P to sphingosine, appears to play a significant role in 
maintaining the S1P gradient, as shown by the increased accumulation of S1P in serum and 
tissue in mice when the Sgpl1 gene was deleted (Peest et al., 2008). Specifically, Peest et al. 
(2008) concluded that S1P lyase is important for the clearance of intracellular S1P; however, 
clearance of extracellular S1P through dephosphorylation to sphingosine and subsequent 
metabolism occurs independently of S1P lyase, ceramide synthase, and sphingosine kinase. 
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Peest et al. (2008) concluded that the ability of all cell types tested (including HEK293, 
Jurkat, LK35.2, HB98, and HTC4 cells) to clear exogenous S1P supports a ubiquitous 
mechanism present in all cells for keeping extracellular S1P and sphingosine levels low, with 
one exception: blood acts as a reservoir for S1P. Specific focus on the S1P gradient in sickle cell 
disease will be valuable because SCD is a disorder of the blood.  
S1P as a Regulator of Cell Physiology 
In endothelial cells, S1P functions in survival, migration, and nitric oxide synthesis and 
can also act to regulate the vascular barrier of endothelium by rearranging their cytoskeletons 
(Cuvillier et al., 1996). Specifically, deletion of the transporter protein gene Spns2 in endothelial 
cells resulted in decreased levels of S1P in plasma, suggesting that endothelial cells play a 
significant role in S1P secretion and maintenance of the S1P gradient via transporter proteins. 
Aoki et al. suggest that S1P plays a role in maintaining integrity of the vascular barrier of 
endothelial cells in part by mediating the redistribution of endothelial integrins from the luminal 
to the basal surface of the cells (2007). 
The role of S1P in contributing to monocyte adhesion to endothelial cells is disputed 
because S1P has been shown to both increase and decrease adhesion and the expression of 
adhesion molecules in endothelial cells depending on whether the cells are stimulated with TNF-
a. Aoki et al. found that S1P pretreatment of endothelial cells inhibited monocyte adhesion 
independently from the expression of ICAM-1, VCAM-1, and E-selectin and was prevented by 
blocking S1P1 and S1P3 receptors as well as several proteins. Inhibition of integrins a5b1 and 
avb3 prevented monocyte to endothelial cell adhesion (Aoki et al., 2007). 
Hughes et al. (2008) demonstrate that S1P can facilitate the phenotypic change from 
inflammatory to anti-inflammatory in macrophages largely through activation of the receptor 
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S1P1. At a concentration near what is seen in blood (500 nM), S1P was shown to reduce the 
inflammatory effects of LPS by suppressing several inflammatory cytokines, including TNF-a, 
MCP-1, IL-12, COX-2, and MIP2 and enhancement of Arg I expression and reduced induction 
of iNOS, demonstrating an important point for any potential S1P therapies for sickle cell disease 
(Hughes et al., 2008).  
Cuvillier et al. (1996) demonstrated that S1P can reduce several characteristic responses 
of apoptosis in HL-60 and U937 cells, including intranucleosomal DNA fragmentation and 
typical changes in morphology, that were induced by C2-ceramide treatment, sphingomyelinase 
treatment, and stimulation of sphingomyelinase through the ligands TNF-α and Fas. Stimulation 
of protein kinase C inhibited apoptosis induced by ceramide by increasing intracellular levels of 
S1P. An inhibitor of sphingosine kinase, the enzyme that produces S1P by phosphorylating 
sphingosine, was used and the previous decrease in apoptosis was not observed. These results 
suggest that S1P and ceramide play important roles in regulating programmed cell death 
(Cuvillier et al., 1996).  
Gude et al. (2008) examined the role of S1P and SphK1 in apoptosis to determine if S1P 
could be a “come-and-get-me” signaling molecule for macrophages. Treatment of Jurkat and 
U937 leukemia cells with the SphK1 inhibitors DMS and DHS induced apoptosis and increased 
the expression of SphK1, as did treatment with the proapoptotic drug doxorubicin, and resulted 
in a more than 3-fold increase in S1P secretion. These effects were significantly reduced by 
apoptosis inhibitor ZVAD. S1P was shown to act as a chemoattractant for primary monocytes 
and macrophages, maximally at 10 nM and 1 nM, respectively (Gude et al., 2008). 
The recruitment of anti-inflammatory monocytes in addition to phenotypic changes to 
anti-inflammatory states may be mediated by the receptors S1P3 and S1P1. Awojoodu et al. 
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(2013) showed that treatment of inflamed tissue in mice with FTY720, an S1P1/3 agonist, 
resulted in increased recruitment of anti-inflammatory monocytes to the targeted tissue through 
increased anti-inflammatory and reduced pro-inflammatory cytokine secretion, which was not 
observed in S1P3 knockout mice. It was also found that anti-inflammatory monocytes expressed 
more S1P3. Hughes et al. (2008) found that S1P facilitates the phenotypic change from 
inflammatory to anti-inflammatory in macrophages derived from mouse bone marrow largely 
through activation of the receptor S1P1 by suppressing several inflammatory cytokines, including 
TNF-a, MCP-1, IL-12, COX-2, and MIP2, enhancement of Arg I expression, and reduced 
induction of iNOS. 
Microparticles 
A new area of research that has arisen recently involves microparticles. Microparticles 
(MPs) are important signaling molecules for innate immunity that have been shown to be derived 
from the cell membrane of dying or activated cells (Gauley and Pisetsky, 2010) and to have 
significant levels of bioactive sphingolipids like S1P (Ratajczak et al., 2006). Conversion of 
membrane sphingomyelin to ceramide by acid sphingomyelinase (SMase) can result in 
microparticle production (Bianco et al., 2009).  
Gauley and Pisetsky found that in response to several Toll-like receptor ligands, MP 
release increased, and this release was linked to (1) NO production through studies inhibiting 
iNOS, which impeded MP production, and (2) incubation with NO donors, which increased MP 
production (2010). NO production is associated with macrophage activation (Green et al., 1990; 





MATERIALS AND METHODS 
Density Fractionation of Blood and Characterization of Microparticles 
Whole blood samples were obtained from males and females homozygous for sickle (SS) 
or normal (AA) hemoglobin through the Sickle Cell Foundation of Georgia. Donors on 
hydroxyurea, chronic transfusion, or who had experienced a recent crisis were excluded from 
this study.  
Isolation of Peripheral Blood Mononuclear Cells and Red Blood Cells 
Whole blood samples were diluted 1:1 in ice-cold PBS and centrifuged against a Ficoll-
Paque density gradient (density: 1.077g/mL; GE Healthcare) for 30 minutes at 400 RCF at 4˚C to 
allow separation of the plasma, buffy coat layer, and packed red blood cells. After centrifugation, 
blood plasma and packed red cells were collected. Peripheral blood mononuclear cells (PBMCs) 
were washed in PBS and pelleted by centrifugation at 300 RCF for 10 minutes. Contamination of 
red blood cells in the PBMC layer was removed using red blood cell lysis buffer (0.83% 
ammonium chloride, 0.1% potassium bicarbonate, and 0.0037% EDTA) for 7 minutes followed 
by washing three times in PBS. 
RBC Density Fractionation 
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RBCs were separated into high and low density fractions according to a protocol by 
D’Alessandro et al. (2013). Briefly, 8 Percoll solutions of varying density were made with 
Percoll, BSA, Hepes, NaCl and KCl and stacked in order of decreasing density, from bottom to 
top, in Beckman ultra-clearTM tubes 9/16 x 3
1/2 in. (14 x 89 mm). The stacked gradient was pre-
centrifuged at 20,000 RCF for 20 minutes. 300µL of packed RBCs were added to 1.5mL of 5mM 
Na2HPO4, 154mM NaCl, 5mM Glucose and 1mM PMSF and centrifuged at 200 RCF for 10 
minutes at 4C. The supernantant was discarded, and this process was repeated twice. The cells 
were resuspended in 1.5mL of 95% glucose. The RBC sample was loaded slowly on top of the 
Percoll gradient and centrifuged at 41,000rpm for 30 minutes using a Beckman SW 41 Ti rotor. 
The highest and lowest density RBC fractions were collected using a syringe and washed in PBS 
with 0.8% NaCl. 
Microparticle Harvest and CFSE Staining 
MP were harvested by ultracentrifugation of AA or SS blood diluted 10-fold in PBS. P3 
MP were obtained by ultracentrifugation of diluted blood at 2000 RCF for 20 minutes at 4oC. 
The supernatant was ultracentrifuged at 3000 RCF for 10 minutes at 4oC, and the resulting 
supernatant was ultracentrifuged at 37,000 RCF for 1 hour at 4oC. The supernatant was removed, 
and the MP were resuspended in PBS. P2 MP were obtained by ultracentrifugation of diluted 
blood at 10,000 RCF for 15 minutes at 4oC. The supernatant was spun at 200,000 RCF for 1 hour 
at 4oC to obtain P4 MP.  
MP were stained with CFSE at a 1:1 dilution for 20 minutes at room temperature 
followed by ultracentrifugation at 16,000 RCF for 20 minutes at 10oC. The supernatant was 
removed and the MPs were resuspended in PBS. 
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Flow Cytometry for Microparticle Quantification 
Plasma and packed RBC were fractionated and isolated from donors as described above 
and incubated with antibodies against CD41 (catalog #Ab19690, Abcam), Glycophorin A 
(catalog #Ab91163, Abcam) and Annexin V (catalog #640906, Biolegend). Cells were counted 
with Accucheck counting beads (catalog #PCB100, Life Technologies) and analyzed on a BD 
FACS Aria flow cytometer.  
AA/SS Blood Microparticle Characterization 
SEM Sample Preparation 
Cells fixed with 2.5% glutaraldehyde fixative in 0.1 M cacodylate buffer (pH 7.4) were 
placed on a Poly-L-Lysine coated silicon wafer (5 x 5 mm), washed with same buffer and then 
post fixed in 1% osmium tetroxide with 1.5% potassium ferrocyanide in 0.1 M cacodylate buffer 
for one hour. Cells were subsequently rinsed 2 or 3 exchanges of de-ionized water. This was 
followed by dehydration through an ethanol series ending with three exchanges of 100% 
absolute ethanol. The samples were then placed into individual ventilated processing vessels in 
fresh absolute ethanol and placed into a Polaron E3000 critical point drying unit wherein the 
ethanol was exchanged for liquid CO2. The liquid CO2 was eventually brought to its critical point 
of 1073 psi at 31°C and allowed to slowly vent. The dried samples were then secured to labeled 
aluminum SEM stubs and coated with approximately 20 nm of chromium using an Denton DV-
602 turbo magnetron sputter coater (Denton Vaccum, LLC., Moorestown, NJ). Sample were then 




TEM Sample Preparation 
5 µl microparticle suspension was place on a 400 mesh carbon coated copper grid that 
had been made hydrophilic by glow discharge.  After 5 minutes, the grid was rinsed by briefly 
touching the sample side with one drop of distilled water. The residual water on grid was then 
removed by dragging the side of grid on a piece of filter paper. For negative staining, 5 µl 1% 
aqueous phosphotungstic acid (pH 6.5) was applied onto grid immediately after water removal, 
and then removed as described above after 30 seconds. The grid was let completely dry before 
viewing on a JEOL JEM-1400 transmission electron microscope (JEOL Ltd, Tokyo, Japan) 
equipped with a Gatan US1000 2k x2k CCD camera ((Gatan, Inc., Pleasanton, CA). 
Size Quantification 
MP size was evaluated by taking perpendicular measurements in ImageJ of MP diameter 
from TEM images. The average of the two measurements was taken and converted from pixels 
to nanometers using the length in pixels of the scale bar. The average diameter for each group 




Neutral and acidic sphingomyelinase (SMase) activity were measured with a 
sphingomyelinase fluorometric assay kit (catalog # 10006964, Cayman Chemical Company). For 
neutral SMase activity, the reaction was performed in a neutral buffer at a pH of 7.4. For acidic 
SMase activity, the reaction was performed in an acidic buffer at a pH of 5. Briefly, 10µL of 
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samples (plasma, whole blood or RBC) were combined with alkaline phosphatase and a 
fluorometric sphingomyelin substrate. The reaction involving SMase hydrolyzes sphingomyelin 
to form ceramide and phosphorylcholine. Alkaline phosphatase hydrolyzes phosphorylcholine to 
form choline. Choline is then oxidized by choline oxidase to produce betaine and H2O2. H2O2, in 
the presence of horseradish peroxidase, reacts with ADHP to yield fluorescent resorufin, which 
was measured on a plate reader at an excitation wavelength of 535nm and emission wavelength 
of 590nm after 30 minutes. 
Acid sphingomyelinase expression was measured with a sphingomyelinase absorbance 
ELISA assay kit (catalog # SEB360Hu, USCN Life Science). 10µL sample was loaded into 
wells in a 96 well plate ELISA kit pre-coated with a monoclonal antibody against acid SMase 
(catalog #MAB360Hu22, USCN Life Science). Expression was measured by reading the 
absorbance at 450nm. 
Ceramidase Expression 
Alkaline ceramidase (ACER1) expression was measured with a ceramidase absorbance 
ELISA assay kit (catalog # CSB-EL001151HU, CUSABio). 10µL sample was loaded into wells 
in a 96 well plate ELISA kit pre-coated with a monoclonal antibody against alkaline ceramidase 
(ACER1). Expression was measured by reading the absorbance at 450nm. 
SK1/2 Expression 
Sphingosine kinase 1 and 2 expression were measured by western blotting using 
antibodies against sphingosine kinase 1 (catalog #1000-6822, Caymen Chemical Company) or 
sphingosine kinase 2 (catalog #AB37977, Abcam). An equal amount of protein was loaded onto 
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the gels and near IR dyes were used to stain the relevant bands. Expression is expressed as 
relative fluorescent units. 
Lipid Extraction and S1P/Sphingosine Quantification 
Lipids were extracted following a protocol from Shaner et al. (2009). Briefly, 15-150µL 
of whole blood, plasma or RBC was transferred into 13 × 100 mm borosilicate tubes with a 
Teflon-lined caps (catalog #60827-453, VWR, West Chester, PA). 500µL of CH3OH, 250µL of 
CHCl3 and 10µL of C17 Sph+C17 S1P (Cayman Chemicals) internal standard were added to the 
sample and the samples were sonicated at room temperature for 30 seconds. The single phase 
mixture was incubated at 48°C overnight in a water bath and cooled before 75 µl of 1 M KOH in 
CH3OH was added. Samples were sonicated for 5 minutes and shaken in a 37°C water bath for 2 
hours. Samples were cooled and glacial acetic acid was added to bring the extract to neutral pH. 
Samples were centrifuged to remove the insoluble residue and the supernatant was collected. The 
supernatant was placed in glass vials and dried for 6 hours using a nitrogen blow down system. 
The dried residue was reconstituted in 300µL of methanol and analyzed using a Shimadzu LC-10 
AD VP binary pump system coupled to a Perkin Elmer Series 200 autoinjector coupled to a 4000 
quadrupole linear-ion trap (QTrap) LC-MS/MS system for S1P and sphingosine quantification. 
Cell Culture 
THP-1 
Human THP-1 monocytes (ATCC) were maintained in RPMI-1640 medium (Sigma-
Aldrich) supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin, and 0.05 mM 
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β-mercaptoethanol at 37°C in a 5% CO2 atmosphere. All cells were maintained and all 
incubations were performed under these conditions unless mentioned otherwise 
Macrophage Polarization 
THP-1 monocytes were seeded on PDL-coated coverslips and differentiated to M0 
macrophages with 100 nM phorbol myristate acetate (PMA) for 72 hours. M0 macrophages were 
subsequently polarized to M1 macrophages with 5 mg/mL LPS and 10 µg/mL IFN-γ or to M2 
macrophages with 454.5 ng/mL IL-4 for 24 hours. 
HUVEC 
HUVEC (ATCC) were maintained in CS-C Serum Supplemented Medium (Sigma-
Aldrich) in gelatin-coated flasks at 37°C in a 5% CO2 atmosphere. After the cells were 80% 
confluent, they were passaged into new media. GFP-HUVEC were obtained through transfection 
with a EF1α-eGFP vector and were a kind gift of the Platt laboratory at the Georgia Institute of 
Technology. 
Cell Staining, Fixation and Confocal Microscopy 
As appropriate, monocytes were stained with 10 µM Calcein AM (Life Technologies) for 
1 hour before co-incubation. For assays measuring adherence, adherent cells were washed twice 
with PBS and were fixed with 4% paraformaldehyde for 20 minutes. Cells were stained with 
Hoechst (Life Technologies) in PBS and mounted with VECTASHIELD Mounting Medium 
(Vector Laboratories). Slides were imaged using a Zeiss 700 laser scanning confocal microscope. 
THP-1 and HUVEC Co-Culture/Adhesion 
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GFP-HUVEC were seeded in an 8 chamber slide (3 x 105 cells/chamber) and grown to 
confluence. THP-1 were co-incubated with HUVEC under the conditions described below. The 
chambers were washed gently and the nonadherent THP-1 monocytes were removed and counted 
using a hemocytometer. Adherent cells were fixed and stained as described above.  
S1P Treatment 
HUVEC and THP-1 monocytes received vehicle or 1μM S1P treatment for 1 hour. Cells 
were washed with media, and HUVEC were co-incubated with 1 x 105 THP-1 monocytes for 4 
hours.  
RBC Co-Culture 
THP-1 monocytes were incubated with red blood cells derived from AA or SS donors at 
a 1:10 ratio of THP-1 monocytes:RBCs for 18 hours. HUVEC were co-incubated with 1 x 105 
THP-1 monocytes and 1 x 106 RBCs for 4 hours.  
Quantification for Adhesion 
Confocal images of each chamber were used to obtain the ratio of adherent THP-1 
monocytes:HUVEC for the adhesion studies. The number of each cell type present in each image 
was quantified based on the morphology of the nuclei and the DAPI, GFP, and Calcein AM 
stains. ImageJ was used to quantify the nuclei present in at least 5 fields of view from each 
chamber. The live counts obtained for non-adherent THP-1 monocytes were used to calculate the 
percent of adherent cells based on the initial seeding density of THP-1 monocytes. 
AA/SS RBC Microparticle Internalization 
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THP-1 monocytes were seeded at a density of 2 x 105 cells/well on PDL-coated 
coverslips and polarized to M0 macrophages as described previously. CFSE-stained SS or AA 
MPs were added at a density of 1 x 106/well. After 30 or 120 minute incubations, the conditioned 
media was removed from each well and uninternalized MPs were quantified as described above 
with a BD FACS Aria flow cytometer. M0 macrophages were washed with PBS and 
permeabilized with 0.5% Triton (Sigma Aldrich) for 5 minutes, fixed as described above, and 
stained with rhodamine phalloidin (Life Technologies) at a concentration of 5 µL/1 mL sample. 
Cells were washed and mounted as described above.  
Macrophage Microparticle Treatment and Luminex Cytokine Secretion 
THP-1 monocytes were seeded at a density of 2 x 105 cells/well on PDL-coated 
coverslips and polarized to M0, M1, and M2 macrophages as described previously. After 
treatment of the macrophages with SS MP for 1, 2, or 6 hours, the conditioned media was 
removed and a protease inhibitor was added at a 1:100 dilution. RIPA buffer was added to each 
well, and the cells were removed by scraping and were left on ice for 20 minutes. The cell lysate 
was centrifuged at 200 RCF and the supernatant was combined with a protease inhibitor at a 
1:100 dilution. Samples were stored at -80oC. Anti-inflammatory and inflammatory cytokines 
were assessed by a Milliplex MAP Human Cytokine/Chemokine Premixed 42 Plex Assay 
(catalog # MPXHCYTO60KPMX42, Millipore) on the Luminex platform as per the 
manufacturer’s instructions.  




Packed RBC were isolated from SS donors as described above. Amitriptyline (catalog 
#A8404, Sigma) was prepared at four different concentrations in sterile PBS. 100,000 cells were 
placed in wells of a 24 well plate in the presence of the four different concentrations of 
amitriptyline and incubated at 37°C for 1 or 24 hours. Flow cytometry was used to quantify RBC 
and microparticles as described above. 
In vivo 
Wild-type C57BL/6 mice were obtained from The Jackson Laboratories; Heterozygous 
AS and homozygous SS mice were initially obtained from the sickle transgenic breeding colony 
at Georgia Institute of Technology. Townes’ model sickle transgenic mice were heterozygous 
(AS) or homozygous (SS) for the sickle mutation. To determine sickle status, whole blood was 
obtained from each animal via retro-orbital capillary draws. Whole blood was lysed with distilled 
water and diluted 1:1 in a 50% glycerol solution. Blood samples were then run on a Native 
PAGE gel and hemoglobin was visualized using a liquid tetramethylbenzidine stain (34% EtOH, 
32% liquid 3,3',5,5’-tetramethylbenzidine, 2% acetic acid, 1% H2O2); sickle hemoglobin has a 
smaller electrophoretic migration distance than normal hemoglobin. Mice in all studies were 
male, 8–12 wk old, and weighed 18–25 g. Amitriptyline was injected at 4 different doses via 
intraperitoneal administration and blood was collected via retro-orbital capillary draws. RBC and 
microparticles in blood were quantified as described above with a BD FACS Aria flow 
cytometer. All surgical procedures and animal care protocols were approved by the Georgia 





Dysregulation of sphingolipid metabolism in SCD 
A sphingomyelinase fluorometric assay kit was used to measure neutral and acid 
sphingomyelinase activity in AA and SS plasma and RBC. Sphingomyelinase converts 
sphingomyelin to ceramide (Figure 2). Neutral sphingomyelinase activity was low and was not 
significantly different in AA and SS plasma (Figure 3A). A slight elevation was seen in neutral 
sphingomyelinase activity in SS RBC (Figure 3B). Acid sphingomyelinase expression did not 
differ in RBC or plasma for SS vs. AA (Figure 3E); however, acid sphingomyelinase activity 
was elevated in SS RBC and plasma (Figure 3C and 3D) as well as in high density (sickled) RBC 
in comparison to low density RBC (Figure 3F). Acid sphingomyelinase activity was 
approximately 10-fold higher in RBCs than in plasma (Figure 3C and 3D).  
 
Figure 3. Acid and Neutral Sphingomyelinase activity in AA and SS RBC and plasma. 
Donor blood was harvested and fractionated in a Ficoll density gradient to separate plasma and 
RBC. A plate based assay for sphingomyelinase activity was performed at a neutral pH on 
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plasma (A) and RBC (B). Neutral sphingomyelinase activity was very low or undetectable in 
both plasma (A) and RBC (B). SMase activity, while still low, was significantly increased in SS 
RBC (B) relative to AA RBC. This is likely due to residual (sub-optimal) acid SMase activity at 
neutral pH or activation of neutral SMase. A plate based assay for acid sphingomyelinase 
activity was performed on plasma (C) and RBC (D). Acid sphingomyelinase activity was 
elevated in both plasma and RBC from SCD donors relative to non-diseased donors. A plate 
based ELISA for sphingomyelinase expression was performed on plasma and RBC (E). 
Sphingomyelinase expression was not altered in the plasma (left) or RBC (right) of those living 
with SCD. Packed RBC from AA and SS donors were stacked onto Percoll density 
discontinuous layers and spun with ultracentrifugation to separate two distinct density (high and 
low) fractions of cells. F) High density RBC had higher sphingomyelinase activity than low 
density RBC. Low density RBC from SS donors had much higher sphingomyelinase activity 
than low density AA cells and high density RBC from SS donors had much higher 
sphingomyelinase activity than high density AA cells. Morphological differences were apparent 
between the four fractions (G) Scale bar = 5μm. * p < 0.05 measured in a t-test. 
 
Acid ceramidase and sphingosine kinase 1 and 2 expression were quantified using 
ELISAs. Ceramidase converts ceramide to sphingosine, and sphingoskine kinase phosphorylates 
sphingosine to produce S1P (Figure 2). Acid ceramidase 1 expression is unaltered in SS RBC 
(Figure 4A) but is elevated in SS plasma (Figure 4B). The expression of sphingosine kinase 1 
was unaltered, but sphingosine kinase 2 expression was significantly elevated in SS RBC and 
plasma (Figure 4C-4F). HPLC was used to quantify S1P and sphingosine in whole blood, RBC, 
and plasma. S1P and sphingosine were significantly elevated in SS whole blood (Figure 4G), 
plasma (Figure 4H), and RBC (Figure 4I). S1P and sphingosine levels were over 10-fold higher 




Figure 4. Alkaline ceramidase, sphingosine kinase 2, S1P and sphingosine elevated in SCD. 
Donor blood was harvested and fractionated in a Ficoll density gradient to separate plasma and 
RBC. A plate based assay for alkaline ceramidase (ACER1) expression was performed on RBCs 
(A) and plasma (B). ACER1 expression was not altered in SCD RBC. ACER1 was not detected 
in the plasma of those without SCD but was elevated in the plasma of those with SCD. RBC 
were fractionated from donor blood and lysed in RIPA buffer. C) Western blotting shows 
expression of both SK1 and SK2, but only SK2 was visibly elevated in SS RBC. D) Relative fold 
changes in SK1 and K2 expression reveal a significant increase in SK2 expression in SS RBC. 
E-F) Donor plasma was assessed for SK2 expression and plasma from those living with SS had 
significantly more SK2, relative to AA, suggesting that SK2 is secreted during SCD. Lipids were 
extracted from donor samples and sphingosine and S1P levels in whole blood (G), plasma (H) 





Monocyte adhesion is enhanced by S1P pre-treatment and by co-incubation with SCD 
RBCs 
THP-1 monocytes and HUVECs were co-incubated after treatment with S1P. When 
HUVECs were treated with S1P, no change in adhesion was seen in comparison to the control 
after a 4 hour incubation. Adhesion increased over 4-fold when THP-1 monocytes were treated 
with S1P (Figure 5A), as seen in Figure 5C. A significant increase in monocyte adhesion was 
seen in as little as 4 hours (Figure 5B).  
 
Figure 5. S1P treatment of monocytes enhances endothelial adhesion. A) HUVEC were 
grown to confluence and co-incubated with THP-1 monocytes for 4 hours after 1 hour vehicle 
treatment, 1μM S1P treatment of HUVEC or 1μM S1P treatment of monocytes. S1P treatment of 
monocytes significantly enhanced the adherent monocyte : endothelial cell ratio after 4 hours. B-
C) THP-1 monocytes were treated with 1μM S1P and allowed to adhere to HUVEC for 4 hours. 
S1P treatment did not affect early adhesion but resulted in an increase in monocyte adhesion 
after 240 minutes (B). Representative confocal images (C). Scale bar = 10μm. * p < 0.05 




AA RBCs or SS RBCs (sickled RBCs are circled in red) were incubated with THP-1 
monocytes for 18 hours (Figure 6A), followed by a 4 hour co-incubation with HUVEC. 
Adhesion was increased almost 4-fold for monocytes treated with SS RBC in comparison to AA 
RBC (Figure 6B), as seen in Figure 6C. 
 
Figure 6. Co-incubation of SS RBC and monocytes enhances endothelial adhesion. A) AA 
(left) or SS (right) RBC were co-incubated with THP-1 monocytes (10:1) for 18 hours. Sickle 
RBC (red circles) are visible. B-C) Co-incubation of THP-1 monocytes with SS RBC 
significantly enhanced monocyte:HUVEC ratio after 4 hour adhesion (B). Representative images 
(C) show enhanced THP-1 monocytes (red cells) adhered to a HUVEC (green) monolayer. Scale 




Microparticles are elevated in SCD and modulate cytokine production in myeloid cells 
Microparticles in AA and SS plasma and RBC were quantified using flow cytometry 
(Figure 7A-D). Microparticles were slightly elevated in SS plasma (Figure 7B) and were 
significantly elevated by almost 2-fold in SS RBCs (Figure 7D). Microparticles were separated 
by size using differential ultracentrifugation and were imaged using TEM (Fig 7E). The small 
microparticles (P4) had an average diameter of approximately 200 nm, and large microparticles 
(P2) had an average diameter of approximately 300 nm. The overall population of microparticles 
had an average diameter of approximately 200 nm. HPLC was used to quantify the lipid profile 
of the microparticles. In SS microparticles, sphingosine and S1P (Figure 7F) were elevated by 
over three-fold, and ratio of ceramide to sphingomyelin (Figure 7G) was significantly elevated as 
well. 
Microparticles were observed to interact with macrophages. SS microparticles were 
internalized by M0 macrophages in as little as 30 minutes (Figure 7H). Treatment of M0, M1, 
and M2 macrophages with SS microparticles increased inflammatory cytokine production and 
secretion. Specifically, MIP-1a, TNF-α, and IL-6, three cytokines associated with SCD vaso-
occlusive crises (Keikhaei et al., 2013), were elevated in M0, M1, and M2 macrophages in 
comparison to untreated cells (Figure 7I and Figure 7J). Notably, IL-6 was the cytokine that was 
most elevated when normalized to non-treated cells, with the highest fold change observed in M0 




Figure 7. RBC derived microparticles are significantly increased in SCD and are 
internalized by macrophages and enhance cytokine production. Donor blood was 
fractionated and microparticles were quantified in plasma and RBC via flow cytometry. A) 
Annexin-V+ microparticles were observed in the plasma of AA (left) and SS (right) donors. B) 
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Microparticle concentration was between 2000 and 2500 microparticles per 100μL plasma. C) 
Annexin-V+ microparticles were observed in the RBC fraction of AA (left) and SS (right) 
donors. D) Microparticle concentration was around 100,000 per 100μL for AA RBC but 
significantly elevated (250,000 per 100μL) for SS RBC. Microparticles were harvested from 
packed RBC at three different serial ultracentrifugation speeds for one hour. E) TEM images 
were taken of microparticles harvested at 10,000 (P2), 37,000xg (P3) or 200,000xg (P4) for one 
hour. Scale bar = 200nm. F) P2 microparticles were around 300nm on average while P3 and P4 
microparticles were around 200nm. G) P3 microparticles were labeled with CFSE and incubated 
with M0 THP-1 macrophages for 30 (top) or 120 (bottom) minutes. Scale bar = 10μm. Flow 
cytometry was used to quantify the number of particles internalized (H). A higher proportion of 
cells was internalized in 30 minutes than 120 minutes suggesting that microparticles can be 
internalized and subsequently secreted but there were no differences between AA and SS 
microparticles. I-J) SCD RBC-derived P3 microparticles were incubated with M0 (black), M1 
(red) or M2 (blue) macrophages for 1 (left), 2 (middle) or 6 (right) hours. Microparticle 
incubation enhanced the production (I) and secretion (J) of inflammatory cytokines MIP-1a, 
TNF-a and IL-6 relative to untreated cells (dotted line). * p < 0.05 measured in t-test.  
 
Inhibition of acid sphingomyelinase reduces the generation of microparticles in vivo in mice 
and in vitro in red blood cells  
Microparticles were quantified by flow cytometry in packed SS RBCs treated with 
amitriptyline for 24 hours in vitro. Both the percent of microparticles out of total events and the 
ratio of microparticles to RBCs were reduced in a dose-dependent fashion, and this reduction 
was significant using 100 μM amitriptyline (Figure 8A-D). In vivo, 10 mpk amitriptyline reduced 
acid sphingomyelinase activity significantly after 24 hour treatment and reduced microparticle 




Figure 8. Amitriptyline reduces microparticle generation in RBC. A-B) Flow cytometry 
showing microparticles and RBC at 1 hour (A) and 24 hours (B). C-D) 100μM Amitriptyline 
significantly reduces the percentage of microparticles produced from SS RBC (C). 10 and 
100μM Amitriptyline significantly reduces the proportion of microparticles produced from SS 
RBC (D). E) 10mpk Amitriptyline significantly reduces acid sphingomyelinase activity in 
C57/Bl6 mice 24 hours after injection. F) Amitriptyline reduces microparticle generation relative 
to vehicle treated groups as early as 1 hour after injection. * p<0.05 compared to vehicle, & 







SCD is associated with severe vaso-occlusive crises initiated by RBC sickling (Conran et 
al., 2009; Hebbel et al., 1980). Belcher et al. (2000) note that myeloid cells are activated in the 
disease state, which contributes to vaso-occlusion through the increased adherence of these cells. 
Recent studies indicate that microparticles produced in SCD contribute to the activation of these 
cells (Mause and Weber, 2010; Tantawy et al., 2012). This work illustrates a connection between 
dysregulated sphingolipid metabolism and the pathology of vaso-occlusion in sickle cell disease 
through microparticle-mediated activation of myeloid cells and is suggestive of a pathway that 
may be open for pharmacological intervention. 
Acid sphingomyelinase is associated with microparticle generation (Bianco et al., 2009) 
and has been observed to have increased activity during inflammation (Wong et al., 2000) and 
under membrane stress in red blood cells (Lopez et al., 2012). In accordance with these findings, 
increased activity was observed for acid sphingomyelinase RBC and plasma (Figure 3), as 
expected due to the membrane stress induced by RBC sickling. In further support of these 
findings, microparticles were observed to be elevated in SCD (Figure 7A-D), corroborating 
previous studies (Shet et al., 2003). In addition, microparticles were shown to have an increased 
ratio of ceramide to sphingomyelin (Figure 7G), which is indicative of acid sphingomyelinase 
activity through the hydrolysis of ceramide to produce sphingomyelin (Figure 2). SS 
microparticles were also characterized by significantly elevated S1P and sphingosine (Figure 
7F). Dysregulation was observed for other enzymes and lipids in the sphingolipid metabolic 
pathway in SCD, including increased activity of ceramidase I in plasma (Figure 4B) and 
sphingosine kinase 2 (Figure 4C-4F) in RBC and plasma. S1P and sphingosine were both 
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observed to be elevated in whole blood (Figure 4G), plasma (Figure 4H), and RBCs (Figure 4I) 
in SCD. 
Microparticle treatment increased the production and secretion of the inflammatory 
cytokines MIP-1α, IL-6, and TNF-α in macrophages (Figure 7). These specific cytokines have 
been associated with inflammation and vaso-occlusive crises in SCD (Keikhaei et al., 2013) and 
appear to induce an inflammatory phenotype in even non-inflammatory macrophages. IL-6 was 
constitutively produced and secreted in M0 and M2 macrophages in response to microparticle 
treatment, suggesting that microparticles may play a role in altering macrophage phenotype.  
Additional studies elucidated sphingolipid dysregulation as a key factor initiating the 
activation of myeloid cells in SCD. Focus was placed on S1P as the most bioactive sphingolipid 
and the only sphingolipid with receptors. Recent studies have associated S1P with the 
recruitment of monocytes through the activity of S1P receptor 3 (Awojoodu et al., 2013; Keul et 
al., 2011). A physiological concentration of S1P increased monocyte adhesion to endothelial 
cells over four-fold (Figure 5), as did co-incubation with SS RBC (Figure 6). Together, these 
studies suggest that the elevation of S1P observed in RBCs, microparticles, and plasma in SCD 
may contribute to vaso-occlusion through RBC- or microparticle-mediated interactions and 
subsequent recruitment of these cells. Additional studies examining the direct effect of 
microparticles on myeloid cell adhesion will confirm these preliminary findings. 
This pathway, through which RBC sickling initiates dysregulation of the sphingolipid 
metabolic pathway and contributes to vaso-occlusion, is a prime target for pharmacological 
treatment. Our results demonstrate that treatment with amitriptyline significantly reduced the 
generation of microparticles by RBCs in vitro and in vivo (Figure 8). Through the established 
connection between microparticles and myeloid cell activation, amitriptyline should impede 
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vaso-occlusion and inflammation by reducing microparticle generation and thus the recruitment, 
activation, and adhesion of myeloid cells. These results are promising, but additional studies are 
needed to directly relate the inhibition of acid sphingomyelinase to reduced recruitment of 
myeloid cells in vivo to confirm the effect of amitriptyline on myeloid cell recruitment and 
adhesion in SCD.  
Currently, the primary treatment for sickle cell disease is blood transfusion, which 
replaces sickled red blood cells temporarily but does not influence the underlying causes of 
sickling (Health, 2002). The use of amitriptyline and other drugs to act on the sphingolipid 
metabolic pathway have shown to be dysregulated in sickle cell disease may prove to be a more 
effective treatment option. Pharmacological targeting of sphingolipids promise long-term 
treatment of the root causes of this devastating disease that is associated with chronic pain, 
stroke, organ failure, and low life expectancy (Belcher et al., 2000; Harmatz et al., 2000; 
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